Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a heart condition called cardiac ATTR amyloidosis (a disease where abnormal proteins build up in the heart), based on recently established medical guidelines, and who are about to begin a medication called tafamidis at the University Hospital Zurich
Who may not be able to join:
- People who are already taking another disease-modifying treatment for their condition, such as a medication called patisiran
- People who have an ongoing irregular heart rhythm originating in the upper chambers of the heart (confirm with trial site)
- People whose heartbeat is currently being controlled or assisted by a pacing device in the lower chambers of the heart (confirm with trial site)
- People who have previously had a heart attack affecting a specific area of the heart called the septum (the wall between the heart's chambers)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dominik C Benz, MD, Universität Zürich
Phone: +41432531191
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in FAPI uptake
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.